{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:59:37Z","timestamp":1790672377991,"version":"4.1.0"},"reference-count":28,"publisher":"American Veterinary Medical Association (AVMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["javma"],"published-print":{"date-parts":[[2021,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec id=\"s001\">\n<jats:title>OBJECTIVE<\/jats:title>\n<jats:p>To identify physical examination and perioperative CBC variables in dogs with splenic hemangiosarcoma (HSA) that could aid in predicting progression-free interval (PFI) and overall survival time (OST) in affected dogs.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"s002\">\n<jats:title>ANIMALS<\/jats:title>\n<jats:p>70 client-owned dogs with splenic HSA treated with splenectomy and chemotherapy between September 2004 and October 2016.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"s003\">\n<jats:title>PROCEDURES<\/jats:title>\n<jats:p>A retrospective search of the University of Minnesota Veterinary Medical Center medical records database was performed to identify dogs with splenic HSA treated with splenectomy and with evidence in the medical records of intent to treat with chemotherapy. Data collection included dog signalment and body surface area, results from CBCs performed within 6 days before to 2 days after splenectomy, whether dogs had hemoabdomen or received transfusions, and tumor stage. Hematocrit, WBC count, and platelet count were treated as categorical variables (divided into terciles: above, within, or below reference limits) because of variation among reference intervals for the numerous analyzers used. Associations between variables and PFI or OST were investigated with Cox regression analyses, and hazard ratios (HRs) for a shorter PFI or OST were reported. Population Pearson correlation coefficient (\u03c1) analysis was performed to identify potential associations between variables of interest.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"s004\">\n<jats:title>RESULTS<\/jats:title>\n<jats:p>Stage 3 HSA was identified as a negative prognostic indicator of PFI (HR, 6.6) and OST (HR, 4.5). Perioperative thrombocytopenia was similarly associated with shorter PFI (HR, 2.2) and OST (HR, 2.0). Results for Hct correlated (\u03c1 = 0.58) with those for platelet count, and although our findings did not indicate a notable association between anemia and shorter PFI, such could not be ruled out.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"s005\">\n<jats:title>CONCLUSIONS AND CLINICAL RELEVANCE<\/jats:title>\n<jats:p>The prognostic value of thrombocytopenia warrants further substantiation to understand causal and mechanistic connections, and the presence of thrombocytopenia ultimately may prove valuable in guiding treatment recommendations for dogs with splenic HSA.<\/jats:p>\n<\/jats:sec>","DOI":"10.2460\/javma.258.6.630","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T19:57:38Z","timestamp":1615233458000},"page":"630-637","source":"Crossref","is-referenced-by-count":27,"title":["Retrospective evaluation of thrombocytopenia and tumor stage as prognostic indicators in dogs with splenic hemangiosarcoma"],"prefix":"10.2460","volume":"258","author":[{"given":"Alison R.","family":"Masyr","sequence":"first","affiliation":[{"name":"Department of Veterinary Clinical Sciences, University of Minnesota, Saint Paul, MN 55108."},{"name":"Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL 61802."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron K.","family":"Rendahl","sequence":"additional","affiliation":[{"name":"Department of Veterinary and Biomedical Sciences, University of Minnesota, Saint Paul, MN 55108."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber L.","family":"Winter","sequence":"additional","affiliation":[{"name":"Department of Clinical Investigation Center, University of Minnesota, Saint Paul, MN 55108."},{"name":"Department of College of Veterinary Medicine, and Animal Cancer Care and Research Program, University of Minnesota, Saint Paul, MN 55108."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Borgatti","sequence":"additional","affiliation":[{"name":"Department of Veterinary Clinical Sciences, University of Minnesota, Saint Paul, MN 55108."},{"name":"Department of Clinical Investigation Center, University of Minnesota, Saint Paul, MN 55108."},{"name":"Department of College of Veterinary Medicine, and Animal Cancer Care and Research Program, University of Minnesota, Saint Paul, MN 55108."},{"name":"Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime F.","family":"Modiano","sequence":"additional","affiliation":[{"name":"Department of Veterinary Clinical Sciences, University of Minnesota, Saint Paul, MN 55108."},{"name":"Department of College of Veterinary Medicine, and Animal Cancer Care and Research Program, University of Minnesota, Saint Paul, MN 55108."},{"name":"Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455."},{"name":"Stem Cell Institute, University of Minnesota, Minneapolis, MN 55455."},{"name":"Center for Immunology, University of Minnesota, Minneapolis, MN 55455."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1272","reference":[{"key":"R1","series-title":"J Small Anim Pract","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/j.1748-5827.1995.tb02769.x","article-title":"A review of pathological diagnoses made from 87 canine splenic biopsies","volume":"36","author":"Day MJ","year":"1995","unstructured":"Day MJ, Lucke VM, Pearson H. A review of pathological diagnoses made from 87 canine splenic biopsies. J Small Anim Pract 1995;36:426\u2013433.10.1111\/j.1748-5827.1995.tb02769.x"},{"key":"R2","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1939-1676.1997.tb00085.x","article-title":"Pathologic factors affecting postsplenectomy survival in dogs","volume":"11","author":"Spangler WL","year":"1997","unstructured":"Spangler WL, Kass PH. Pathologic factors affecting postsplenectomy survival in dogs. J Vet Intern Med 1997;11:166\u2013171.10.1111\/j.1939-1676.1997.tb00085.x"},{"key":"R3","series-title":"Withrow and MacEwen's small animal clinical oncology","first-page":"679","article-title":"Hemangiosarcoma","author":"Thamm DH","year":"2013","unstructured":"Thamm DH. Hemangiosarcoma. In: Withrow SJ, Vail DM, Page RL, eds. Withrow and MacEwen's small animal clinical oncology. 5th ed. St Louis: Elsevier-Saunders, 2013;679\u2013688."},{"key":"R4","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/j.1939-1676.2007.tb03019.x","article-title":"Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs","volume":"21","author":"Lana S","year":"2007","unstructured":"Lana S, U'ren L, Plaza S,  Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. J Vet Intern Med 2007;21:764\u2013769.10.1111\/j.1939-1676.2007.tb03019.x"},{"key":"R5","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/j.1939-1676.1991.tb00943.x","article-title":"Efficacy and toxicity of vac chemotherapy (vincristine, doxorubicin, and cyclophosphamide) in dogs with hemangiosarcoma","volume":"5","author":"Hammer AS","year":"1991","unstructured":"Hammer AS, Couto CG, Filppi J,  Efficacy and toxicity of vac chemotherapy (vincristine, doxorubicin, and cyclophosphamide) in dogs with hemangiosarcoma. J Vet Intern Med 1991;5:160\u2013166.10.1111\/j.1939-1676.1991.tb00943.x"},{"key":"R6","series-title":"J Am Vet Med Assoc","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2460\/javma.247.4.393","article-title":"Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001\u20132012)","volume":"247","author":"Wendelburg KM","year":"2015","unstructured":"Wendelburg KM, Price LL, Burgess KE,  Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001\u20132012). J Am Vet Med Assoc 2015;247:393\u2013403.10.2460\/javma.247.4.393"},{"key":"R7","series-title":"Can Vet J","first-page":"237","article-title":"Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study","volume":"54","author":"Kahn SA","year":"2013","unstructured":"Kahn SA, Mullin CM, De Lorimier L-P,  Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study. Can Vet J 2013;54:237\u2013242."},{"key":"R8","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1939-1676.2004.tb00162.x","article-title":"Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma","volume":"18","author":"Sorenmo KU","year":"2004","unstructured":"Sorenmo KU, Baez JL, Clifford CA,  Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma. J Vet Intern Med 2004;18:209\u2013213.10.1111\/j.1939-1676.2004.tb00162.x"},{"key":"R9","series-title":"J Am Anim Hosp Assoc","doi-asserted-by":"publisher","first-page":"304","DOI":"10.5326\/JAAHA-MS-6540","article-title":"Adjuvant doxorubicin with or without metronomic cyclophosphamide for canine splenic hemangiosarcoma","volume":"53","author":"Matsuyama A","year":"2017","unstructured":"Matsuyama A, Poirier VJ, Mantovani F,  Adjuvant doxorubicin with or without metronomic cyclophosphamide for canine splenic hemangiosarcoma. J Am Anim Hosp Assoc 2017;53:304\u2013312.10.5326\/JAAHA-MS-6540"},{"key":"R10","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1939-1676.1994.tb03248.x","article-title":"Cutaneous hemangiosarcoma in 25 dogs: a retrospective study","volume":"8","author":"Ward H","year":"1994","unstructured":"Ward H, Fox LE, Calderwood-Mays MB,  Cutaneous hemangiosarcoma in 25 dogs: a retrospective study. J Vet Intern Med 1994;8:345\u2013348.10.1111\/j.1939-1676.1994.tb03248.x"},{"key":"R11","series-title":"J Am Anim Hosp Assoc","doi-asserted-by":"publisher","first-page":"518","DOI":"10.5326\/0390518","article-title":"Acute nontraumatic hemoabdomen in the dog: a retrospective analysis of 39 cases (1987\u20132001)","volume":"39","author":"Pintar J","year":"2003","unstructured":"Pintar J, Breitschwerdt EB, Hardie EM,  Acute nontraumatic hemoabdomen in the dog: a retrospective analysis of 39 cases (1987\u20132001). J Am Anim Hosp Assoc 2003;39:518\u2013522.10.5326\/0390518"},{"key":"R12","series-title":"J Am Anim Hosp Assoc","doi-asserted-by":"publisher","first-page":"417","DOI":"10.5326\/15473317-34-5-417","article-title":"Prognosis for dogs with stage I or II splenic hemangiosarcoma treated by splenectomy alone: 32 cases (1991\u20131993)","volume":"34","author":"Wood CA","year":"1998","unstructured":"Wood CA, Moore AS, Gliatto JM,  Prognosis for dogs with stage I or II splenic hemangiosarcoma treated by splenectomy alone: 32 cases (1991\u20131993). J Am Anim Hosp Assoc 1998;34:417\u2013421.10.5326\/15473317-34-5-417"},{"key":"R13","series-title":"J Am Vet Med Assoc","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.2460\/javma.231.10.1550","article-title":"Epirubicin in the adjuvant treatment of splenic hemangiosarcoma in dogs: 59 cases (1997\u20132004)","volume":"231","author":"Kim SE","year":"2007","unstructured":"Kim SE, Liptak JM, Gall TT,  Epirubicin in the adjuvant treatment of splenic hemangiosarcoma in dogs: 59 cases (1997\u20132004). J Am Vet Med Assoc 2007;231:1550\u20131557.10.2460\/javma.231.10.1550"},{"key":"R14","series-title":"J Am Vet Med Assoc","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2460\/javma.232.4.553","article-title":"Prevalence of hemangiosarcoma in anemic dogs with a splenic mass and hemoperitoneum requiring a transfusion: 71 cases (2003\u20132005)","volume":"232","author":"Hammond TN","year":"2008","unstructured":"Hammond TN, Pesillo-Crosby SA. Prevalence of hemangiosarcoma in anemic dogs with a splenic mass and hemoperitoneum requiring a transfusion: 71 cases (2003\u20132005). J Am Vet Med Assoc 2008;232:553\u2013558.10.2460\/javma.232.4.553"},{"key":"R15","series-title":"J Am Vet Med Assoc","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2460\/javma.251.5.559","article-title":"Evaluation of clinical and histologic factors associated with survival time in dogs with stage II splenic hemangiosarcoma treated by splenectomy and adjuvant chemotherapy: 30 cases (2011\u20132014)","volume":"251","author":"Moore AS","year":"2017","unstructured":"Moore AS, Rassnick KM, Frimberger AE. Evaluation of clinical and histologic factors associated with survival time in dogs with stage II splenic hemangiosarcoma treated by splenectomy and adjuvant chemotherapy: 30 cases (2011\u20132014). J Am Vet Med Assoc 2017;251:559\u2013565.10.2460\/javma.251.5.559"},{"key":"R16","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1939-1676.1991.tb00923.x","article-title":"Hemostatic abnormalities in dogs with hemangiosarcoma","volume":"5","author":"Hammer AS","year":"1991","unstructured":"Hammer AS, Couto CG, Swardson C,  Hemostatic abnormalities in dogs with hemangiosarcoma. J Vet Intern Med 1991;5:11\u201314.10.1111\/j.1939-1676.1991.tb00923.x"},{"key":"R17","series-title":"Can Vet J","first-page":"967","article-title":"Canine visceral hemangiosarcoma treated with surgery alone or surgery and doxorubicin: 37 cases (2005\u20132014)","volume":"59","author":"Batschinski K","year":"2018","unstructured":"Batschinski K, Nobre A, Vargas-Mendez E,  Canine visceral hemangiosarcoma treated with surgery alone or surgery and doxorubicin: 37 cases (2005\u20132014). Can Vet J 2018;59:967\u2013972."},{"key":"R18","series-title":"Mol Cancer Ther","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1158\/1535-7163.MCT-16-0637","article-title":"Safe and effective sarcoma therapy through bispecific targeting of EGFR and uPAR","volume":"16","author":"Borgatti A","year":"2017","unstructured":"Borgatti A, Koopmeiners JS, Sarver AL,  Safe and effective sarcoma therapy through bispecific targeting of EGFR and uPAR. Mol Cancer Ther 2017;16:956\u2013965.10.1158\/1535-7163.MCT-16-0637"},{"key":"R19","series-title":"Vet Comp Oncol","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/vco.12590","article-title":"Impact of repeated cycles of EGF bispecific angiotoxin (eBAT) administered at a reduced interval from doxorubicin chemotherapy in dogs with splenic haemangiosarcoma","volume":"18","author":"Borgatti A","year":"2020","unstructured":"Borgatti A, Fieberg A, Winter AL,  Impact of repeated cycles of EGF bispecific angiotoxin (eBAT) administered at a reduced interval from doxorubicin chemotherapy in dogs with splenic haemangiosarcoma. Vet Comp Oncol 2020;18:664\u2013674.10.1111\/vco.12590"},{"key":"R20","series-title":"Int J Cancer","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1002\/ijc.28187","article-title":"Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors","volume":"133","author":"Schappa JT","year":"2013","unstructured":"Schappa JT, Frantz AM, Gorden BH,  Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors. Int J Cancer 2013;133:1936\u20131944.10.1002\/ijc.28187"},{"key":"R21","series-title":"J Am Vet Med Assoc","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.2460\/javma.242.10.1385","article-title":"Perioperative outcome in dogs with hemoperitoneum: 83 cases (2005\u20132010)","volume":"242","author":"Lux CN","year":"2013","unstructured":"Lux CN, Culp WTN, Mayhew PD,  Perioperative outcome in dogs with hemoperitoneum: 83 cases (2005\u20132010). J Am Vet Med Assoc 2013;242:1385\u20131391.10.2460\/javma.242.10.1385"},{"key":"R22","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/j.1939-1676.1989.tb03092.x","article-title":"Splenomegaly in dogs. Predictors of neoplasia and survival after splenectomy","volume":"3","author":"Johnson KA","year":"1989","unstructured":"Johnson KA, Powers BE, Withrow SJ,  Splenomegaly in dogs. Predictors of neoplasia and survival after splenectomy. J Vet Intern Med 1989;3:160\u2013166.10.1111\/j.1939-1676.1989.tb03092.x"},{"key":"R23","series-title":"Clin Cancer Res","doi-asserted-by":"publisher","first-page":"8782","DOI":"10.1158\/1078-0432.CCR-05-1664","article-title":"The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors","volume":"11","author":"Primeau AJ","year":"2005","unstructured":"Primeau AJ, Rendon A, Hedley D,  The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 2005;11:8782\u20138788.10.1158\/1078-0432.CCR-05-1664"},{"key":"R24","series-title":"J Am Vet Med Assoc","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.2460\/javma.245.12.1382","article-title":"Risk factors for perioperative death in dogs undergoing splenectomy for splenic masses: 539 cases (2001\u20132012)","volume":"245","author":"Wendelburg KM","year":"2014","unstructured":"Wendelburg KM, O'Toole TE, McCobb E,  Risk factors for perioperative death in dogs undergoing splenectomy for splenic masses: 539 cases (2001\u20132012). J Am Vet Med Assoc 2014;245:1382\u20131390.10.2460\/javma.245.12.1382"},{"key":"R25","series-title":"J Vet Med Sci","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1292\/jvms.66.573","article-title":"The incidence of disseminated intravascular coagulation in dogs with malignant tumor","volume":"66","author":"Maruyama H","year":"2004","unstructured":"Maruyama H, Miura T, Sakai M,  The incidence of disseminated intravascular coagulation in dogs with malignant tumor. J Vet Med Sci 2004;66:573\u2013575.10.1292\/jvms.66.573"},{"key":"R26","series-title":"Vet Comp Oncol","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1111\/vco.12131","article-title":"Doxorubicin chemotherapy for presumptive cardiac hemangiosarcoma in dogs","volume":"14","author":"Mullin CM","year":"2016","unstructured":"Mullin CM, Arkans MA, Sammarco CD,  Doxorubicin chemotherapy for presumptive cardiac hemangiosarcoma in dogs. Vet Comp Oncol 2016;14:e171\u2013e183.10.1111\/vco.12131"},{"key":"R27","series-title":"Porto Biomed J","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.pbj.2017.05.005","article-title":"Role of platelets in immune system and inflammation","volume":"2","author":"Sonmez O","year":"2017","unstructured":"Sonmez O, Sonmez M. Role of platelets in immune system and inflammation. Porto Biomed J 2017;2:311\u2013314.10.1016\/j.pbj.2017.05.005"},{"key":"R28","series-title":"Blood","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1182\/blood-2013-11-462432","article-title":"Emerging roles for platelets as immune and inflammatory cells","volume":"123","author":"Morrell CN","year":"2014","unstructured":"Morrell CN, Aggrey AA, Chapman LM,  Emerging roles for platelets as immune and inflammatory cells. Blood 2014;123:2759\u20132767.10.1182\/blood-2013-11-462432"}],"container-title":["Journal of the American Veterinary Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/258\/6\/javma.258.6.630.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/258\/6\/javma.258.6.630.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/258\/6\/javma.258.6.630.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T01:29:02Z","timestamp":1696555742000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/258\/6\/javma.258.6.630.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":28,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.2460\/javma.258.6.630","relation":{},"ISSN":["0003-1488"],"issn-type":[{"value":"0003-1488","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,15]]}}}